Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + nab-paclitaxel + bevacizumab + radiotherapy in advanced extrapulmonary neuroendocrine carcinoma (second-line or later)
ChiCTR2600117826Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in neuroendocrine carcinoma (NEC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
avelumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on ChiCTR2600117826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117826.